JP4633482B2 - Medical disinfectant cleaning composition - Google Patents
Medical disinfectant cleaning composition Download PDFInfo
- Publication number
- JP4633482B2 JP4633482B2 JP2005008916A JP2005008916A JP4633482B2 JP 4633482 B2 JP4633482 B2 JP 4633482B2 JP 2005008916 A JP2005008916 A JP 2005008916A JP 2005008916 A JP2005008916 A JP 2005008916A JP 4633482 B2 JP4633482 B2 JP 4633482B2
- Authority
- JP
- Japan
- Prior art keywords
- medical
- acid
- cleaning
- cleaning composition
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
本発明は、手術・検査等により血液等の体液で汚れた医療器具洗浄時に、殺菌と洗浄を同時に行うことで作業者の感染リスクを低減し、器具洗浄を容易にする医療用殺菌洗浄剤組成物に関する。 The present invention relates to a medical sterilization detergent composition that reduces the risk of infection of workers by performing sterilization and cleaning simultaneously when cleaning a medical instrument soiled with a body fluid such as blood by surgery or inspection, and facilitates instrument cleaning. Related to things.
使用後の医療用器具及びその他医療用機器を用手洗浄する場合、洗浄前に器具を一度洗浄剤溶液に浸漬し、付着乾燥した血液汚れを溶解させることが一般的に行われており、主に酵素(プロテアーゼ)を含有する洗浄剤が用いられてきた。近年、院内感染の問題が大きくなってきており、様々な状況で感染リスクを低減させることが病院においての必須課題となっている。術後血液で汚染された、即ち感染因子となる細菌あるいはウイルスが血液中に存在している可能性のある医療器具を用手洗浄する場合、感染の確率は高いと考えられる。感染リスクを低下させる目的で医療器具を使用直後に例えばアルデヒド含有消毒剤に浸漬すれば、血液は消毒剤によって凝固し浸漬による汚れ膨潤効果が失われるばかりか、用手洗浄において多大な負担が発生する。 When manually cleaning medical equipment and other medical equipment after use, it is common practice to immerse the equipment in a detergent solution before washing to dissolve the attached and dried blood stains. A detergent containing an enzyme (protease) has been used. In recent years, the problem of nosocomial infection has increased, and reducing the risk of infection in various situations has become an essential issue in hospitals. It is considered that the probability of infection is high when manually washing a medical device that is contaminated with blood after surgery, that is, a bacterium or virus that may become an infectious agent may be present in the blood. Immediately after use, for example, an aldehyde-containing disinfectant to reduce the risk of infection, blood is coagulated by the disinfectant and the soil swelling effect due to immersion is lost. To do.
これらの問題を解決するために、特許文献1では、イオン性界面活性剤、アルカノールアミンおよび蛋白質分解酵素の組み合わせによる洗浄剤を提案している。また、特許文献2では、プロテアーゼ、ポリオキシエチレン−ポリオキシプロピレンブロックポリマーおよび酵素安定剤を含む中性から弱アルカリ性の内視鏡洗浄剤を開示している。
しかしながら、特許文献1では依然消毒を行ってから浸漬を行うことが必要であり、洗浄プロセスの簡略化には至らず、医療従事者にとって好ましいとは言い難い。また、術後の医療器具を特許文献1あるいは2の洗浄剤を希釈して浸漬する場合、殺菌成分が添加されていないため感染のリスクが低減できるとは考えられない。 However, in Patent Document 1, it is still necessary to perform immersing after sterilization, which does not lead to simplification of the cleaning process and is not preferable for medical staff. Moreover, when diluting and dipping the cleaning device of Patent Document 1 or 2 after the operation, it is not considered that the risk of infection can be reduced because no bactericidal component is added.
そこで本発明は、浸漬等の簡易な操作でも体液が付着した医療器具に対して優れた殺菌効果と洗浄効果を示す医療用殺菌洗浄剤組成物を提供することを課題とする。 Then, this invention makes it a subject to provide the medical sterilization cleaning composition which shows the outstanding sterilization effect and washing | cleaning effect with respect to the medical device which the bodily fluid adhered even by simple operation, such as immersion.
本発明は、(a)酸性物質〔以下、(a)成分という〕、(b)塩基性物質〔以下、(b)成分という〕、(c)タンパク質分解酵素、並びに(d)ポリリジン、クロロヘキシジン及び第4級アンモニウム塩型殺菌剤から選ばれる一種以上一種以上を、(a)+(b)が0.5モル/kg以上となるように配合してなる医療用殺菌洗浄剤組成物に関する。
The present invention comprises (a) an acidic substance (hereinafter referred to as component (a)), (b) a basic substance (hereinafter referred to as component (b)), (c) a proteolytic enzyme, and (d) polylysine, chlorohexidine and The present invention relates to a medical disinfectant composition comprising one or more quaternary ammonium salt disinfectants selected so that (a) + (b) is 0.5 mol / kg or more.
また、本発明は、(c)タンパク質分解酵素〔以下、(c)成分という〕、(d)ポリリジン、クロロヘキシジン及び第4級アンモニウム塩型殺菌剤から選ばれる一種以上〔以下、(d)成分という〕、並びに0.5モル/kg以上のイオン性物質を含有する医療用殺菌洗浄剤組成物に関する。 In addition, the present invention provides at least one or more selected from (c) proteolytic enzyme (hereinafter referred to as (c) component), (d) polylysine, chlorohexidine and quaternary ammonium salt fungicide [hereinafter referred to as (d) component. And a medical disinfectant cleaning composition containing 0.5 mol / kg or more of an ionic substance.
また、本発明は、上記本発明の医療用殺菌洗浄剤組成物を用いて医療器具を洗浄する方法に関する。 Moreover, this invention relates to the method of wash | cleaning a medical instrument using the medical disinfection cleaning composition of the said invention.
また、本発明は、(a)成分、(b)成分、(c)成分、(d)成分、並びに水を、イオン性物質が0.5モル/kg以上となるように混合し、医療用殺菌洗浄剤組成物を製造する方法に関する。 Moreover, this invention mixes (a) component, (b) component, (c) component, (d) component, and water so that an ionic substance may be 0.5 mol / kg or more, and for medical use. The present invention relates to a method for producing a sterilizing detergent composition.
本発明の医療用殺菌洗浄剤組成物によれば、細菌あるいはウィルスの汚染が懸念される血液等の体液が付着した医療器具に対して、希釈液への浸漬のみの簡便な操作で、十分な洗浄と殺菌を同時に行うことができる。このため、医療従事者の用手洗浄における負担が軽減できると同時に、感染リスクを低減できる。しかも、本発明の組成物は酵素安定性にも優れている。 According to the medical disinfectant cleaning composition of the present invention, a simple operation such as immersion in a diluting solution is sufficient for a medical device to which a body fluid such as blood, which may be contaminated with bacteria or viruses, is attached. Cleaning and sterilization can be performed simultaneously. For this reason, the burden on the manual cleaning of the medical staff can be reduced, and at the same time, the risk of infection can be reduced. Moreover, the composition of the present invention is also excellent in enzyme stability.
<(a)成分>
(a)成分は水中で酸性を呈する物質であり、酸であれば有機酸、無機酸を問わず何れでも良く、酸の水素原子の一部が金属原子等で置換されていてもよく、1種又は2種以上を使用することができるが、好ましくはリン酸類(具体的にはリン酸1カリウム、リン酸1ナトリウム、リン酸等)、ホウ酸、炭酸、あるいはアミノカルボン酸、オキシカルボン酸(具体的には酒石酸、リンゴ酸、クエン酸等)、コハク酸などのキレート能を持つ酸類など用いることができる。好ましくは、リン酸1カリウム、クエン酸、炭酸である。なお、(a)成分からは、(c)成分、(d)成分、後述の(e)成分、及び2価金属を含む物質は除かれる。
<(A) component>
The component (a) is a substance that exhibits acidity in water. Any acid can be used, regardless of whether it is an organic acid or an inorganic acid, and a part of the hydrogen atom of the acid may be substituted with a metal atom or the like. Species or two or more species can be used, but preferably phosphoric acids (specifically, 1 potassium phosphate, 1 sodium phosphate, phosphoric acid, etc.), boric acid, carbonic acid, aminocarboxylic acid, oxycarboxylic acid Acids having chelating ability such as tartaric acid, malic acid, citric acid, etc., and succinic acid can be used. Preferred are monopotassium phosphate, citric acid, and carbonic acid. In addition, (c) component, (d) component, (e) component mentioned later, and the substance containing a bivalent metal are excluded from (a) component.
<(b)成分>
(b)成分は水中でアルカリ性を呈する物質であり、塩基であれば、有機塩基、無機塩基を問わず何れでも良く、1種又は2種以上を使用することができるが、好ましくはリン酸金属塩類(具体的にはリン酸2カリウム、リン酸2ナトリウム等)、炭酸金属塩類(具体的には炭酸ナトリウム、炭酸カリウム等)、アミン類(具体的にはモノエタノールアミン、ジエタノールアミン、トリエタノールアミン等)などを用いることができる。好ましくは、モノエタノールアミン、炭酸ナトリウムである。なお、(b)成分からは、(c)成分、(d)成分、後述の(e)成分、及び2価金属を含む物質は除かれる。
<(B) component>
Component (b) is a substance that exhibits alkalinity in water, and any base can be used regardless of whether it is an organic base or an inorganic base, and one or more can be used, but preferably a metal phosphate. Salts (specifically dipotassium phosphate, disodium phosphate, etc.), metal carbonates (specifically sodium carbonate, potassium carbonate, etc.), amines (specifically monoethanolamine, diethanolamine, triethanolamine) Etc.) can be used. Preferred are monoethanolamine and sodium carbonate. The component (b) excludes the component containing the component (c), the component (d), the component (e) described later, and a divalent metal.
本発明でいうイオン性物質とは、水中で解離し得る物質を指すが、組成物での状態は問わない。ただし、イオン性物質からは、(c)成分、(d)成分、後述の(e)成分、及び2価金属を含む物質は除かれる。また、芒硝等の中性の塩はイオン性物質に含まれる。 The ionic substance referred to in the present invention refers to a substance that can dissociate in water, but the state in the composition is not limited. However, (c) component, (d) component, (e) component mentioned later, and the substance containing a bivalent metal are excluded from an ionic substance. In addition, neutral salts such as mirabilite are included in ionic substances.
<(c)成分>
(c)成分としては、中性からアルカリ側pHにタンパク分解活性の至適を持つものであれば何れでも良いが、pH8.5(40℃)での活性が100〜20000AHU(酵素濃厚液1kgあたり)、更に200〜10000AHUもののが、洗浄性と経済性の点で好ましい。この活性は、アンソンヘモグロビン法により測定されたものである。(c)成分としては例えば、サビナーゼ、エバラーゼ(ノボザイム社製)、ビオプラーゼ30G、ビオプラーゼAPL−30(ナガセケムテックス社製)、エンチロンSA(洛東化成工業社製)、GODO−BAP(合同酒精社製)、ピュラフェクト4000L(ジェネンコア協和社製)、コロラーゼ7089、コロラーゼTS〔エービー・エンザイムズ(AB Enzymes)社製〕等が挙げられる。(c)成分は、1種又は2種以上を使用することができる。
<(C) component>
The component (c) may be any component as long as it has an optimal proteolytic activity from neutral to alkaline pH, but the activity at pH 8.5 (40 ° C.) is 100 to 20000 AHU (1 kg of enzyme concentrate 1 kg). In addition, those of 200 to 10,000 AHU are preferable in terms of detergency and economy. This activity was measured by the Anson hemoglobin method. As the component (c), for example, sabinase, everase (manufactured by Novozyme), bioprelase 30G, bioprelase APL-30 (manufactured by Nagase ChemteX), enchilon SA (manufactured by Toto Kasei Kogyo Co., Ltd.), GODO-BAP (joint sake company) Manufactured), Purefect 4000L (manufactured by Genencor Kyowa), corolase 7089, corolase TS (manufactured by AB Enzymes) and the like. (C) 1 type (s) or 2 or more types can be used for a component.
<(d)成分>
(d)成分は殺菌剤であり、ポリリジン、クロロヘキシジン及び第4級アンモニウム塩型殺菌剤から選ばれる一種以上が使用される。第4級アンモニウム塩としては、ジメチルジアルキル(炭素数6〜20)アンモニウム塩、ベンゼトニウム塩、ベンザルコニウム塩(例えば塩化ベンザルコニウム等)が好ましい。(d)成分としては、洗浄効果の観点から、ポリリジンが好ましい。
<(D) component>
The component (d) is a fungicide, and one or more selected from polylysine, chlorohexidine and quaternary ammonium salt type fungicides are used. As a quaternary ammonium salt, a dimethyldialkyl (C6-C20) ammonium salt, a benzethonium salt, and a benzalkonium salt (for example, benzalkonium chloride, etc.) are preferable. As the component (d), polylysine is preferable from the viewpoint of cleaning effect.
ポリリジンは、結合状態により、α−ポリリジン、ε−ポリリジンに分けられるが、本発明では安全性の面から、ε−ポリリジンを使用することが望ましい。 Polylysine is classified into α-polylysine and ε-polylysine depending on the binding state. In the present invention, it is desirable to use ε-polylysine from the viewpoint of safety.
(d)成分は、組成物中に0.01〜1重量%、更に0.02〜0.5重量%、特に0.02〜0.25重量%含有されることが、殺菌効果と洗浄効果の点で好ましい。 The component (d) is contained in the composition in an amount of 0.01 to 1% by weight, more preferably 0.02 to 0.5% by weight, particularly 0.02 to 0.25% by weight. This is preferable.
本発明の医療用殺菌洗浄剤組成物は、酵素を安定化させる観点から(e)酵素安定化剤〔以下、(e)成分という〕を含有することが好ましい。(e)成分としては、カルシウムあるいはその塩(例えば塩化カルシウム、乳酸カルシウム等、両性イオン性化合物(例えばグリシン、ベタイン等)などが挙げられるが、カルシウムあるいはその塩が好ましく用いられる。たとえば、塩化カルシウムを用いた場合、組成物中に0.01〜2重量%、更に0.05〜1重量%の濃度で配合することで、酵素活性を安定化することができ、安定な洗浄性を有する殺菌洗浄組成物を提供することが可能である。(e)成分は、1種又は2種以上を使用することができる。 The medical disinfectant cleaning composition of the present invention preferably contains (e) an enzyme stabilizer [hereinafter referred to as (e) component] from the viewpoint of stabilizing the enzyme. Examples of the component (e) include calcium or a salt thereof (for example, calcium chloride, calcium lactate and the like, zwitterionic compounds (for example, glycine and betaine)), and calcium or a salt thereof is preferably used. Can be used to stabilize the enzyme activity by blending in the composition at a concentration of 0.01 to 2% by weight, and further 0.05 to 1% by weight. A cleaning composition can be provided, and one or more components (e) can be used.
<医療用殺菌洗浄剤組成物>
本発明の医療用殺菌洗浄剤組成物は、最終組成物中の(a)成分と(b)成分の濃度(a)+(b)が、0.5モル/kg以上、好ましくは0.5〜5モル/kg、更に好ましくは1〜3.5モル/kgとなるよう、各成分を配合してなる。この濃度を満たした上で、両者を(a)/(b)が0.01〜10、更に0.05〜1のモル比で含有することが洗浄力の点から好ましい。
<Medical disinfectant cleaning composition>
In the medical disinfectant cleaning composition of the present invention, the concentration (a) + (b) of the component (a) and the component (b) in the final composition is 0.5 mol / kg or more, preferably 0.5. Each component is blended so as to be ˜5 mol / kg, more preferably 1 to 3.5 mol / kg. It is preferable from the viewpoint of detergency that both are contained in a molar ratio of (a) / (b) of 0.01 to 10, and more preferably 0.05 to 1 after satisfying this concentration.
(a)成分の配合量は、重量基準では、組成物中に好ましくは0.01〜20重量%、より好ましくは0.1〜15重量%、特に好ましくは0.5〜10重量%である。また、(b)成分の配合量は、組成物中に好ましくは0.1〜30重量%、より好ましくは0.5〜25重量%、特に好ましくは0.5〜20重量%である。 The amount of component (a) is preferably 0.01 to 20% by weight, more preferably 0.1 to 15% by weight, and particularly preferably 0.5 to 10% by weight in the composition on a weight basis. . Moreover, the compounding quantity of (b) component becomes like this. Preferably it is 0.1-30 weight%, More preferably, it is 0.5-25 weight%, Especially preferably, it is 0.5-20 weight%.
(a)成分の配合量は、モル基準では、組成物中に好ましくは5ミリモル/kg〜2モル/kg、より好ましくは10ミリモル/kg〜1.5モル/kg、特に好ましくは50ミリモル/kg〜1モル/kgである。また、(b)成分のの配合量は、モル基準では、組成物中に好ましくは10ミリモル/kg〜3モル/kg、より好ましくは50ミリモル/kg〜2.5モル/kg、特に好ましくは50ミリモル/kg〜2モル/kgである。 The amount of component (a) is preferably 5 mmol / kg to 2 mol / kg, more preferably 10 mmol / kg to 1.5 mol / kg, particularly preferably 50 mmol / kg in the composition on a molar basis. kg to 1 mol / kg. The amount of component (b) is preferably 10 mmol / kg to 3 mol / kg, more preferably 50 mmol / kg to 2.5 mol / kg, particularly preferably in the composition on a molar basis. 50 mmol / kg to 2 mol / kg.
本発明の医療用殺菌洗浄剤組成物は、イオン性物質を0.5モル/kg以上含有するが、0.5〜5モル/kg、更に0.5〜3.5モル/kg含有することが、洗浄力の点から好ましい。組成物中のイオン性物質の量は、配合が既知であればそのまま算出でき、また配合が未知であっても組成物を直接分析する、蒸発残渣を分析する等の手法により算出できる。分析装置としては、液体クロマトグラフィー等が使用できる。 The medical disinfectant cleaning composition of the present invention contains 0.5 mol / kg or more of an ionic substance, but 0.5 to 5 mol / kg, and further 0.5 to 3.5 mol / kg. Is preferable from the viewpoint of detergency. The amount of the ionic substance in the composition can be calculated as it is if the formulation is known, and even if the formulation is unknown, it can be calculated by a technique such as analyzing the composition directly or analyzing the evaporation residue. As the analyzer, liquid chromatography or the like can be used.
本発明の医療用殺菌洗浄剤組成物は、原液のpHは25℃で7〜10であることが好ましく、原液ないし水等で希釈した洗浄液として用いることができるが、使用時(例えば、医療用殺菌洗浄剤組成物を100〜500倍に希釈した水溶液、25℃)のpHは7〜9が好ましい。一般に、血液等の体液が付着した医療器具の殺菌洗浄用途では、アルカリ性が高いことは洗浄力の点では有利と考えられるが、医療器具に錆を発生させたり、酵素の保存安定性を低下させたりすることが懸念されるため、高アルカリ領域の組成物を用いることは困難である。pH7〜9の範囲では、錆発生の問題はないものの洗浄力は不利となるが、本発明では、(a)〜(d)成分を組み合わせること、特に(a)成分と(b)成分の濃度を前記範囲としイオン強度を高めること及び(c)成分を含有させることで、このようなpH領域でも相乗的に洗浄力を向上でき、また(d)成分を選択することで優れた殺菌力を所定の希釈時にも得ることができる。 In the medical disinfectant cleaning composition of the present invention, the pH of the stock solution is preferably 7 to 10 at 25 ° C. and can be used as a stock solution or a cleaning solution diluted with water or the like. The pH of the aqueous solution obtained by diluting the sterilizing detergent composition 100 to 500 times (25 ° C.) is preferably 7 to 9. In general, for sterilization and cleaning of medical devices to which body fluid such as blood adheres, high alkalinity is considered advantageous in terms of cleaning power, but it may cause rusting in medical devices and reduce enzyme storage stability. It is difficult to use a composition in a high alkali region. In the range of pH 7 to 9, there is no problem of rust generation, but the cleaning power is disadvantageous. However, in the present invention, the combination of the components (a) to (d), particularly the concentrations of the components (a) and (b). By increasing the ionic strength within the above range and containing the component (c), it is possible to synergistically improve the detergency even in such a pH range, and by selecting the component (d), excellent bactericidal power can be obtained. It can also be obtained at a predetermined dilution.
本発明の医療用殺菌洗浄剤組成物は、100〜500倍に水で希釈してpH7〜9の洗浄液として使用されることが好ましい。特に、(d)成分、中でもポリリジンを0.2〜100ppm、更に0.4〜50ppm、より更に0.4〜25ppm含有する洗浄液であることが好ましい。 The medical disinfectant cleaning composition of the present invention is preferably used as a cleaning solution having a pH of 7-9 after being diluted 100 to 500 times with water. In particular, the cleaning liquid preferably contains 0.2 to 100 ppm, more preferably 0.4 to 50 ppm, and still more preferably 0.4 to 25 ppm of component (d), especially polylysine.
本発明の医療用殺菌洗浄剤組成物には、上記成分に加えて、表面張力を低下し汚れへの浸透性を高めるために界面活性剤を用いることができる。また、可溶化剤として、プロピレングリコール、エチレングリコール、ソルビトール等の多価アルコール類を用いることができる。 In addition to the above components, a surfactant can be used in the medical sterilizing detergent composition of the present invention in order to reduce the surface tension and increase the permeability to dirt. Moreover, polyhydric alcohols, such as propylene glycol, ethylene glycol, and sorbitol, can be used as a solubilizer.
本発明の医療用殺菌洗浄剤組成物を用いた洗浄方法は、該組成物を100〜500倍に水で希釈した20〜50℃の洗浄液を調製し、該洗浄液に、手術室等で使用した血液等の体液汚れの付着した鉗子、ピンセット、クーパーなどの医療器具を浸漬することが好ましい。この方法では、医療器具全体が洗浄液に浸漬されていることが好ましく、また、浸漬時間は5〜30分が好ましい。これにより、医療器具が洗浄でき、かつ血液等の体液内の細菌あるいはウイルスの増殖能を直ちに阻害することができる。 In the cleaning method using the medical disinfectant cleaning composition of the present invention, a cleaning solution at 20 to 50 ° C. was prepared by diluting the composition 100 to 500 times with water, and this cleaning solution was used in an operating room or the like. It is preferable to immerse medical instruments such as forceps, tweezers, and coopers to which body fluid such as blood adheres. In this method, it is preferable that the entire medical instrument is immersed in the cleaning liquid, and the immersion time is preferably 5 to 30 minutes. As a result, the medical instrument can be washed, and the ability of bacteria or viruses in body fluids such as blood to be immediately inhibited.
実施例1及び比較例1〜3
表1に示す医療用殺菌洗浄剤組成物の400倍希釈水溶液を調製し、これを評価用洗浄液として、抗菌力と洗浄力を下記に示す方法により測定した。なお、評価用洗浄液は、洗浄力の評価では4°DH硬水を用いて、抗菌力の評価では馬血0.2重量%水溶液を用いてそれぞれ調製した。また、表1の組成物の酵素安定性を下記に示す方法により測定した。これらの結果を表1に示す。
Example 1 and Comparative Examples 1-3
A 400-fold diluted aqueous solution of the medical disinfectant cleaning composition shown in Table 1 was prepared, and this was used as a cleaning liquid for evaluation, and antibacterial power and cleaning power were measured by the following methods. The evaluation cleaning solution was prepared using 4 ° DH hard water for evaluation of detergency, and 0.2% by weight aqueous solution of horse blood for evaluation of antibacterial activity. Moreover, the enzyme stability of the composition of Table 1 was measured by the method shown below. These results are shown in Table 1.
(1)洗浄力評価
モデル汚れは、1500rpm、10分で遠心した馬保存血の沈殿部40重量%を均一に混合し、ステンレス板(SUS430)に20μLを2cm2の広さに塗りつけ、80℃、1時間にて熱変性したものとした。
(1) Detergency evaluation model soil, 1500 rpm, the precipitate portion 40 wt% of the horses banked blood was centrifuged at 10 min homogeneously mixed, smeared with 20μL of the breadth of the 2 cm 2 on a stainless steel plate (SUS430), 80 ° C. It was heat-denatured in 1 hour.
まず、モデル汚れを40℃の4°DH硬水に10分間浸漬後、ステンレス板上に洗浄できずに残った馬血中のATPをルシフェラーゼにより発色させて定量する。これをコントロール(洗浄率0%)とする。一方、完全に汚れが落ちた場合(洗浄率100%)の場合のATP量は0である。これらのATP量から、所定APT量を洗浄率に換算できる(検量線法により)。 First, the model soil is immersed in 4 ° DH hard water at 40 ° C. for 10 minutes, and then ATP in horse blood remaining unwashed on the stainless steel plate is developed with luciferase and quantified. This is taken as a control (washing rate 0%). On the other hand, the amount of ATP when the dirt is completely removed (cleaning rate 100%) is zero. From these ATP amounts, the predetermined APT amount can be converted into a cleaning rate (by a calibration curve method).
4°DH硬水に所定濃度になるように洗浄剤組成物を添加した評価用洗浄液に10分間浸漬後のATP量を同様に求め、その値から洗浄率を算出した。 The amount of ATP after immersion for 10 minutes in a cleaning solution for evaluation in which a cleaning composition was added to 4 ° DH hard water so as to have a predetermined concentration was similarly determined, and the cleaning rate was calculated from the value.
(2)抗菌力評価
評価用洗浄液に各種微生物(黄色ブドウ球菌S.aureus、緑膿菌P.aureginosa、キャンディダC.albicans)を103〜104個/mL接種し、室温(25℃)で1時間放置した。その後の評価用洗浄液中の生菌数は、SCD−LPプレートに塗布、35℃、48時間培養にて検出されたコロニーを計測した。その値の初期の菌数に対する比率を1から引いた値を抗菌力とした。
(2) Evaluation of antibacterial activity 10 3 to 10 4 / mL of various microorganisms (S. aureus, P. aureginosa, C. albicans) in the cleaning solution for evaluation, and room temperature (25 ° C.) And left for 1 hour. The number of viable bacteria in the subsequent washing solution for evaluation was applied to an SCD-LP plate and colonies detected by culturing at 35 ° C. for 48 hours were counted. The value obtained by subtracting the ratio of the value to the initial number of bacteria from 1 was defined as antibacterial activity.
(3)酵素安定性評価
表1の医療用殺菌洗浄剤組成物を、50℃で3日保存した後のプロテアーゼ活性を、アンソンヘモグロビン法により測定した。
(3) Enzyme stability evaluation The protease activity after storing the medical germicidal detergent composition of Table 1 at 50 ° C for 3 days was measured by the Anson hemoglobin method.
(注)表中、エバラーゼはノボザイム社製のプロテアーゼ濃厚液(酵素濃度4重量%)〔pH8.5(40℃)での活性が2150AHU(酵素濃厚液1kgあたり)〕であり、ポリオキシエチレンアルキルエーテルは、エチレンオキシド平均付加モル数12のポリオキシエチレンラウリルエーテルである。 (Note) In the table, Evalase is a protease concentrate manufactured by Novozyme (enzyme concentration 4 wt%) [activity at pH 8.5 (40 ° C.) is 2150 AHU (per kg enzyme concentrate)], and polyoxyethylene alkyl The ether is polyoxyethylene lauryl ether having an average addition mole number of ethylene oxide of 12.
実施例2〜5及び比較例4〜6
表2に示す医療用殺菌洗浄剤組成物の200倍希釈水溶液を調製し、これを評価用洗浄液として、抗菌力と洗浄力を実施例1等と同様に測定した。これらの結果を表2に示す。
Examples 2-5 and Comparative Examples 4-6
A 200-fold diluted aqueous solution of the medical disinfectant cleaning composition shown in Table 2 was prepared, and this was used as a cleaning liquid for evaluation. These results are shown in Table 2.
(注)表中、サビナーゼは、ノボザイム社製のプロテアーゼ濃厚液(酵素濃度4重量%)〔pH8.5(40℃)での活性が8400AHU(酵素濃厚液1kgあたり)〕であり、コロラーゼ7089は、エービー・エンザイムズ社製のプロテアーゼ濃厚液(酵素濃度5重量%)〔pH8.5(40℃)での活性が490AHU(酵素濃厚液1kgあたり)〕である。 (Note) In the table, sabinase is a protease concentrated solution (enzyme concentration 4% by weight) manufactured by Novozyme, Inc. [activity at pH 8.5 (40 ° C.) is 8400 AHU (per kg enzyme concentrated solution)], and corolase 7089 is Protease concentrated solution (enzyme concentration: 5% by weight) manufactured by AB Enzymes, Inc. (activity at pH 8.5 (40 ° C.) is 490 AHU (per kg of enzyme concentrated solution)).
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005008916A JP4633482B2 (en) | 2005-01-17 | 2005-01-17 | Medical disinfectant cleaning composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005008916A JP4633482B2 (en) | 2005-01-17 | 2005-01-17 | Medical disinfectant cleaning composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006193684A JP2006193684A (en) | 2006-07-27 |
| JP4633482B2 true JP4633482B2 (en) | 2011-02-16 |
Family
ID=36800009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005008916A Expired - Fee Related JP4633482B2 (en) | 2005-01-17 | 2005-01-17 | Medical disinfectant cleaning composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4633482B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5584613B2 (en) * | 2010-12-28 | 2014-09-03 | 花王株式会社 | Cleaning method for medical equipment |
| JP5587168B2 (en) * | 2010-12-28 | 2014-09-10 | 花王株式会社 | Cleaning composition for medical equipment |
| JP5584614B2 (en) * | 2010-12-28 | 2014-09-03 | 花王株式会社 | Cleaning composition for medical equipment |
| JP6732454B2 (en) * | 2015-12-15 | 2020-07-29 | サラヤ株式会社 | Cleaning disinfectant composition |
| JP2019014823A (en) * | 2017-07-07 | 2019-01-31 | 日華化学株式会社 | Treatment agent composition before washing living organism stain-adhered appliance, and treatment method before washing living organism stain-adhered appliance |
| AU2019293287B2 (en) * | 2018-06-28 | 2021-07-29 | Asp Global Manufacturing Gmbh | Compositions for treatment and methods for making and using the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06256793A (en) * | 1993-03-03 | 1994-09-13 | Kao Corp | Liquid detergent composition |
| SI0730024T1 (en) * | 1995-03-01 | 2000-02-29 | Chemische Fabrik Dr. Weigert (Gmbh & Co.) | Surgical instruments cleaning composition |
| JPH11302694A (en) * | 1998-04-17 | 1999-11-02 | Kao Corp | Solid cleaning composition for hard surfaces |
| JP2001081186A (en) * | 1999-09-09 | 2001-03-27 | Idemitsu Petrochem Co Ltd | Ketone group-containing polymer, its production, builder and detergent composition |
| JP2001228444A (en) * | 2000-02-18 | 2001-08-24 | Chisso Corp | Solution for cleaning and disinfecting contact lenses |
| AUPQ984400A0 (en) * | 2000-09-01 | 2000-09-28 | Novapharm Research (Australia) Pty Ltd | Surfactant sytem |
-
2005
- 2005-01-17 JP JP2005008916A patent/JP4633482B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006193684A (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250221403A1 (en) | Method for Making a Wound Care Composition and Composition Provided Thereby | |
| JP6860734B2 (en) | Liquid cleaning agent composition | |
| JP5476338B2 (en) | Hydrogen peroxide disinfectant containing cyclic carboxylic acid and / or aromatic alcohol | |
| US4661523A (en) | Disinfectant solutions having improved corrosion properties | |
| JPWO2006057311A1 (en) | Hypochlorous acid type germicide composition | |
| US7481973B2 (en) | Composition and process for chemical and thermal disinfection | |
| EP3223611B1 (en) | Two components disinfecting composition containing peracetic acid and chelating agent | |
| JP2009523155A (en) | Enhanced activity biocidal hydrogen peroxide composition | |
| JP4633482B2 (en) | Medical disinfectant cleaning composition | |
| JP2017522378A (en) | Bactericidal composition containing silver ion and quaternary salt | |
| MXPA02000085A (en) | Disinfectants. | |
| JP5095308B2 (en) | Disinfectant composition | |
| CA2028930A1 (en) | Stable hypochlorous acid sterilizing solution and kit | |
| JPWO2014115860A1 (en) | Viricide | |
| US20210108161A1 (en) | Sanitising composition | |
| US20070286907A1 (en) | Germicide composition | |
| AU2026202822A1 (en) | High osmolarity antimicrobial composition containing one or more organic solvents | |
| AU2026202823A1 (en) | High osmolarity antimicrobial composition containing one or more organic solvents | |
| WO2024144564A1 (en) | Acid-containing neutralizer composition | |
| RU2669343C2 (en) | Disinfecting composition | |
| JP2025104365A (en) | Liquid cleaning composition | |
| JP2021091899A (en) | Anti-bacterial detergent composition | |
| HK40001085A (en) | Sanitising composition | |
| HK40001085B (en) | Sanitising composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070718 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101015 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101116 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101117 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 4633482 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131126 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |